Grifols (GRFS) Competitors $8.44 -0.16 (-1.86%) (As of 02:20 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GRFS vs. AEHAW, CLVR, LVTX, MYNZ, ONCSQ, PHVS, PROC, PBMWW, LLY, and NVOShould you be buying Grifols stock or one of its competitors? The main competitors of Grifols include Aesther Healthcare Acquisition (AEHAW), Clever Leaves (CLVR), LAVA Therapeutics (LVTX), Mainz Biomed (MYNZ), OncoSec Medical (ONCSQ), Pharvaris (PHVS), Procaps Group (PROC), Psyence Biomedical (PBMWW), Eli Lilly and Company (LLY), and Novo Nordisk A/S (NVO). Grifols vs. Aesther Healthcare Acquisition Clever Leaves LAVA Therapeutics Mainz Biomed OncoSec Medical Pharvaris Procaps Group Psyence Biomedical Eli Lilly and Company Novo Nordisk A/S Aesther Healthcare Acquisition (NASDAQ:AEHAW) and Grifols (NASDAQ:GRFS) are both manufacturing companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends, profitability and community ranking. Which has preferable earnings & valuation, AEHAW or GRFS? Grifols has higher revenue and earnings than Aesther Healthcare Acquisition. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAesther Healthcare AcquisitionN/AN/AN/AN/AN/AGrifols$7.13BN/A$64.20MN/AN/A Is AEHAW or GRFS more profitable? Company Net Margins Return on Equity Return on Assets Aesther Healthcare AcquisitionN/A N/A N/A Grifols N/A N/A N/A Does the MarketBeat Community believe in AEHAW or GRFS? Grifols received 349 more outperform votes than Aesther Healthcare Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformAesther Healthcare AcquisitionN/AN/AGrifolsOutperform Votes34956.02% Underperform Votes27443.98% Do analysts recommend AEHAW or GRFS? Grifols has a consensus target price of $10.50, suggesting a potential upside of 24.41%. Given Grifols' stronger consensus rating and higher probable upside, analysts clearly believe Grifols is more favorable than Aesther Healthcare Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aesther Healthcare Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Grifols 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Does the media refer more to AEHAW or GRFS? In the previous week, Grifols had 11 more articles in the media than Aesther Healthcare Acquisition. MarketBeat recorded 11 mentions for Grifols and 0 mentions for Aesther Healthcare Acquisition. Aesther Healthcare Acquisition's average media sentiment score of 0.00 beat Grifols' score of -0.05 indicating that Aesther Healthcare Acquisition is being referred to more favorably in the media. Company Overall Sentiment Aesther Healthcare Acquisition Neutral Grifols Neutral SummaryGrifols beats Aesther Healthcare Acquisition on 6 of the 7 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition Export to ExcelMetricGrifolsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E RatioN/A5.5095.1214.22Price / SalesN/A375.021,217.3088.42Price / Cash10.7252.5939.4936.27Price / Book0.6710.276.976.37Net Income$64.20M$153.22M$118.73M$225.56M7 Day Performance-11.62%-1.19%-1.22%-0.02%1 Month Performance-1.52%-6.71%-3.07%2.04%1 Year Performance-11.62%32.39%32.52%28.00% Grifols Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols3.1194 of 5 stars$8.44-1.9%$10.50+24.4%-10.1%$0.00$7.13B0.0023,737AEHAWAesther Healthcare AcquisitionN/A$0.04-20.6%N/A-71.9%$0.00N/A0.002CLVRClever LeavesN/AN/AN/AN/A$0.00$17.42M0.00560LVTXLAVA Therapeutics1.8109 of 5 stars$1.51-0.7%$6.00+297.4%+1.3%$0.00$6.77M0.0060MYNZMainz Biomed2.1647 of 5 stars$0.21-7.6%$3.00+1,350.0%-80.7%$0.00$900,000.00-0.1330Gap DownHigh Trading VolumeONCSQOncoSec MedicalN/AN/AN/AN/A$0.00N/A0.0040PHVSPharvaris1.4783 of 5 stars$20.51+0.0%$33.60+63.8%+34.9%$0.00N/A0.0030PROCProcaps Group1.4941 of 5 stars$0.70+21.7%N/A-77.2%$0.00$409.92M1.505,500Gap UpTrading HaltedHigh Trading VolumePBMWWPsyence BiomedicalN/A$0.01+11.7%N/AN/A$0.00N/A0.00N/AGap UpLLYEli Lilly and Company4.9913 of 5 stars$750.22-0.4%$1,007.94+34.4%+26.0%$712.20B$34.12B80.0043,000Analyst RevisionNVONovo Nordisk A/S4.2387 of 5 stars$103.11-2.1%$144.50+40.1%+1.7%$462.71B$33.71B34.0863,370Options Volume Related Companies and Tools Related Companies AEHAW Alternatives CLVR Alternatives LVTX Alternatives MYNZ Alternatives ONCSQ Alternatives PHVS Alternatives PROC Alternatives PBMWW Alternatives LLY Alternatives NVO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GRFS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
